Tailoring combinatorial cancer therapies to target the origins of adaptive resistance

Abstract

The development of resistance to chemotherapy is a critical yet poorly understood phenomenon driving cancer-related deaths. We recently reported a study that explored the origins of adaptive chemotherapy resistance. During this investigation we unexpectedly discovered that inherent vulnerabilities were unmasked, creating temporal targets for rational combinations of established drugs.